Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis
Related Experiment Video
Updated: Jan 19, 2026

Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery
Alessia Virzì1,2, Armando Andres Roca Suarez1,2, Thomas F Baumert1,2,3,4
1Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, France.
Abstract:
Hepatitis C virus (HCV) is a major cause of liver disease including metabolic disease, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). HCV induces and promotes liver disease progression by perturbing a range of survival, proliferative, and metabolic pathways within the proinflammatory cellular microenvironment. The recent breakthrough in antiviral therapy using direct-acting antivirals (DAAs) can cure >90% of HCV patients. However, viral cure cannot fully eliminate the HCC risk, especially in patients with advanced liver disease or comorbidities. HCV induces an epigenetic viral footprint that promotes a pro-oncogenic hepatic signature, which persists after DAA cure. In this review, we summarize the main signaling pathways deregulated by HCV infection, with potential impact on liver pathogenesis. HCV-induced persistent signaling patterns may serve as biomarkers for the stratification of HCV-cured patients at high risk of developing HCC. Moreover, these signaling pathways are potential targets for novel chemopreventive strategies.
Related Concept Videos
04:46Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery
10:25"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
13:04A Protocol for Analyzing Hepatitis C Virus Replication
09:02Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
07:10Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
10:28A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

